We have previously confirmed clinical performance of a noninvasive, urine-based gene expression assay, EPI, to discriminate ≥GG2 cancer from GG1 and benign disease for men aged ≥50 years undergoing initial biopsy with PSA levels 2–10 ng/mL [8–10]. This evidence concerns the gene KLK3 and cancer.